Marius Calleja, general manager of Maltese contract manufacturer, Starpharma, discusses the company’s current growth strategy and how Starpharma can capitalize on the emergent medical cannabis niche.
Even though you only started as general manager six months ago, can you describe the evolution of Starpharma over the years?
"Several countries are passing laws regarding cannabis for medical usage, but few have allowed manufacturing and demand far exceeds supply. Therefore, we would like to seize the opportunity and position ourselves in this growing market segment."
